

# 1 **Medical Devices Regulation in Zimbabwe: An Evaluation** 2 **of operational readiness**

3 Charles Chiku<sup>1</sup>, Talkmore Maruta<sup>2</sup>, Fredrick Mbiba<sup>3</sup>, Justen Manasa<sup>4</sup>

4 <sup>1</sup> Regulation and Prequalification Department, World Health Organization, Geneva,  
5 Switzerland

6 <sup>2</sup> Programs, African Society for Laboratory Medicine, Lusaka, Zambia

7 <sup>3</sup> Biomedical Research and Training Institute, The Health Research Unit, Harare, Zimbabwe

8 <sup>4</sup> Department of Oncology, Faculty of Medicine and Health Sciences, University of  
9 Zimbabwe, Harare, Zimbabwe

10 **Background:** Regulation of medical devices has seriously lagged, especially in Resource-  
11 Limited Settings (RLS). There are disparities in regulating medical devices; in the African  
12 region, it is below the global average. This may translate into poor access to quality-assured  
13 medical devices and result in undesirable health outcomes. Operational readiness to regulate  
14 medical devices in Zimbabwe at the Medicines Control Authority of Zimbabwe (MCAZ), the  
15 designated National Regulatory Authority (NRA), is vital for planning and implementation.  
16 The study aimed to assess the readiness of the MCAZ to regulate medical devices by  
17 identifying the strengths and gaps and proposing an institutional development plan that can be  
18 monitored and evaluated to assess progress over time.

19 **Methods:** Quantitative study was conducted using the World Health Organization (WHO)  
20 Global Benchmarking Tool+ medical devices (GBT+ medical devices) methodology to  
21 evaluate the medical devices regulatory oversight at the MCAZ. Data were collected between  
22 June and August 2022 using standard checklists to assess the quality of implementation of  
23 medical devices' regulatory functions; National Regulatory System (RS), Registration and  
24 Market Authorisation (MA), Vigilance (VL), Market Surveillance and Control (MC),  
25 Licensing Establishment (LI), Regulatory Inspection (RI), Laboratory Testing(LT), and  
26 Clinical Trials (CTs) Oversight.

27 **Results:** The MCAZ attained maturity level 1, with an RS score of 79%, MA- 44%, VL -27%,  
28 MC- 40%, LI- 62%, RI- 68%, LT- 88%, and CT -18%. Condoms and gloves were the only  
29 regulated medical devices. Indicators on legal provisions, regulations, and guidelines across  
30 the regulatory functions were below the optimum requirement.

31 **Conclusion:** The legal provisions, regulations, and guidelines are inadequate for effectively  
32 regulating medical devices. The medical devices regulation requires review for it to be robust  
33 and fit-for-purpose, responsive, oriented to the outcome, predictable based on a standard and  
34 transparent approach, and the level of scrutiny proportionate to the risk classification of the  
35 medical device.

36

## 37 **Key Words:**

38 Medical Devices, Safety, Quality, Performance, National Regulatory System, Registration and  
39 Market Authorisation, Vigilance, Market Surveillance and Control, Licensing Establishment,  
40 Regulatory Inspection, Laboratory Testing, and Clinical Trials.

**NOTE:** This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

41

## 42 **Introduction**

43 Medical devices are essential for the public to reach the highest health standards. Although  
44 regulations for medicines and vaccines have existed for many years, regulation of medical  
45 devices, including In Vitro Diagnostics (IVDs) medical devices, has seriously lagged,  
46 especially in resource-limited settings (RLS). A medical device is "any instrument, apparatus,  
47 machine, appliance, implant, reagent for in vitro use, software, material, or related article used  
48 for a specific medical purpose" (1,2). An IVD medical device is used to examine human  
49 specimens to provide diagnostic information, monitoring, or compatibility purposes (3).

50

51

### **Medical Device Regulations**

52 Medical Device Regulations are a set of laws and regulations governing clinical trials,  
53 manufacturing, and distribution of medical devices to ensure they are safe and perform as  
54 intended by their manufacturers (4,5). The primary objective of regulating medical devices is  
55 to facilitate access to safe, effective medical devices with acceptable performance and quality  
56 to ensure safety for patients and users.

57

58 Regulatory processes in the African region are not well documented compared to the US Food  
59 and Drug Administration (FDA) and the European Union's European Medicines Agency (6).  
60 However, despite the regulatory processes being well documented in the US and the EU, they  
61 have not been immune to challenges associated with product recalls, adverse incident reports  
62 and removing some medical devices from the market (7,8). These systems are not easily  
63 adoptable by RLS due to their prohibitively high maintenance costs and the capacity required  
64 to ensure continuous improvement. Harmonising regulatory systems across different settings

65 is essential to reduce the regulatory burden on manufacturers and other economic operators in  
66 getting their products on the market. It has also been concluded that poor regulatory systems  
67 in developing countries make it difficult for manufacturers to introduce their products in these  
68 markets, resulting in limited access to them (9,10).

69

70 In general, there are mechanisms to reduce the regulatory burden on manufacturers and the  
71 workload on the regulators. These include convergence, harmonisation, reliance and  
72 recognition. Convergence is an approach that seeks to make regulatory requirements similar  
73 across countries and adopt internationally recognised standards, technical guidance documents,  
74 shared scientific principles and procedures to ensure that public health is protected considering  
75 the local context. It does not necessarily mean the harmonisation of laws. Harmonisation is the  
76 process by which technical guidelines are developed to be uniform across participating  
77 authorities. Reliance is the act whereby the regulatory authority in one jurisdiction takes into  
78 account and bases its decision on an evaluation conducted by another regulatory authority. In  
79 contrast, the relying authority remains responsible for its decisions. The reliance mechanism is  
80 meant to reduce the barriers to access of IVDs due to unclear regulations and a lack of legal  
81 provisions to implement it. Regulatory reliance enables healthcare systems to;

- 82 • accelerate global access to safe and quality health technology,
- 83 • increase efficient use of resources and avoid duplication of efforts,
- 84 • reduce uncertainties for innovators and improve harmonisation in regulation,
- 85 • promote more consistent and robust responses to crises (2).

86 Recognition is a mechanism that allows approval from one regulatory authority to be given  
87 equivalent weight in another jurisdiction. Recognition indicates that evidence of conformity  
88 with the regulatory requirements of country X is sufficient to meet country Y(11).

89

90

91

### **Disparities in Medical Device Regulations**

92 There are disparities in the availability of medical device regulatory services between the global  
93 and WHO Africa (Afro) region. About 40% of countries in the WHO Afro region had no  
94 regulations for medical devices, 32% had some regulations, and 28% had no regulations.

95 In contrast, at the global level, 58% of all WHO member states indicated that they had  
96 regulations on medical devices. Zimbabwe was presented with the element of only placing  
97 medical devices on the market. Premarket and post-market elements were unavailable  
98 according to the survey published in 2016 by the WHO(12). This gap in medical device  
99 regulation between the Afro region and the global average is crucial as it may translate to lower-  
100 quality medical devices and limited patient access to healthcare technologies. The lack of  
101 harmonised regulations may result in a regulatory burden for manufacturers to introduce their  
102 products on the market. The fundamental characteristics of a robust and fit-for-purpose  
103 regulatory system are responsiveness, oriented to the outcome, predictability based on a  
104 standard and transparent approach, and the level of scrutiny to assess the conformity of the  
105 medical devices to set requirements must be proportionate to the risk classification of the  
106 medical device. The regulatory system and institutions must be independent (13).

107

108

### **Medical Device, including IVD Regulations in Zimbabwe**

109 There is a dearth of medical device literature specific to Zimbabwe. Hubner et al. conducted a  
110 study to determine the evolving landscape of medical device regulations in member countries  
111 of the Surgeons of Central, Eastern and Southern Africa (COSECA). Zimbabwe is a member  
112 of COSECA. The study used a systematic review of the literature on medical devices. It was  
113 concluded that Zimbabwe had a legal framework for regulating medical devices, conformity  
114 assessment (evaluation conducted to approve medical devices to be granted market access),

115 and import and export and post-market surveillance for condoms and gloves only (9). Contrary  
116 to the finding, the WHO survey concluded that Zimbabwe only had elements of placing  
117 medical devices on the market without premarket and post-market elements. It is unclear  
118 whether the framework in Zimbabwe has evolved and is robust enough to effectively regulate  
119 medical devices, including IVDs.

120

121 Another study conducted by Mwedzi et al. in monitoring the progress in regulatory systems  
122 strengthening in the Southern African Development Community (SADC)-Zimbabwe is a  
123 member state of SADC. It was determined that the NRAs with a normative legal framework  
124 for medical devices were just above 50%, and less than 50% of the member states had a legal  
125 framework for regulating IVD medical devices or imaging equipment. The study looked at  
126 premarket approval, to a lesser extent, clinical testing and post-marketing surveillance (13).  
127 Furthermore, the results lacked granularity since they were anonymised and unlinked, making  
128 it difficult to conclude the regulatory status of Zimbabwe.

129

130 Similarly, Kniazkov et al. surveyed to map existing frameworks, mechanisms and approaches  
131 to prevention, detection and response (PDR) to Sub-Standard and Falsified (SF) medical  
132 products. Findings pointed to deficiencies in policies and implementation plans despite most  
133 countries having the mandate and legislation to deal with substandard and falsified (SF)  
134 medical products. This study also lacked specific results for Zimbabwe due to unlinking and  
135 anonymising the countries. Moreover, the study was for medical products in general without  
136 specifying medical devices (14).

137

138 A qualitative study to assess the regulation of HIV-Self Testing IVDs in Malawi, Zambia and  
139 Zimbabwe was conducted by Dacombe et al. The study aimed to document the emerging

140 regulatory landscape and perceptions of key stakeholders involved in HIVST policy and  
141 regulation before implementation in three low- and middle-income countries. It was found that  
142 the reference laboratory monitored the quality and performance of HIV-Self Testing IVDs used  
143 in the public sector in all three countries. However, the mandate to regulate HIV-Self Testing  
144 IVDs overlapped between the Medical Laboratory and Clinical Scientists Council of  
145 Zimbabwe and the Medicines Control Authority of Zimbabwe (MCAZ). Stakeholders  
146 indicated they had a poor understanding of the process and requirements for HIVST regulation  
147 and a lack of clarity and coordination between organisational roles (15).

148

149 The extent to which Zimbabwe's regulatory system governance is an essential driver for  
150 implementation has yet to be adequately appraised due to a lack of studies specific to the  
151 Zimbabwean context. Recent studies have shown an absence of medical device regulation  
152 literature in the COSECA region. The same study concluded that Zimbabwe had no formal  
153 regulatory system for medical devices except for gloves and condoms (9). The study also  
154 concluded that MCAZ is a regulatory authority mandated to regulate medical devices.  
155 However, another study examining HIV Self-Testing IVDs in Zambia, Malawi and Zimbabwe  
156 concluded that it was unclear which institution was mandated to regulate IVDs in Zimbabwe  
157 (15).

158

159 Our study aimed to unpack the landscape of medical device regulation in Zimbabwe, focusing  
160 on the MCAZ as the NRA using the GBT + medical devices. The GBT tool was created after  
161 harmonising benchmarking tools for health products. The harmonisation was conducted to  
162 maximise outcomes and reduce the regulatory burden for the NRAs and manufacturers. The  
163 GBT is "a game changer in strengthening national regulatory capacity" through a global  
164 standardised manner of evaluating regulatory systems (16). An effective regulatory system is

165 essential to strengthening health and improving health outcomes. Better health outcomes for  
166 the population are achieved through access to safe medical devices of acceptable quality,  
167 performance and effectiveness. This is the goal of effective medical device regulation.

168 On the one hand, due to SF medical devices and associated economic costs, underdeveloped  
169 regulatory systems may severely affect public health. Underdeveloped regulatory systems are  
170 associated with the regulatory burden for manufacturers to comply with unclear or different  
171 regulations when seeking premarket approvals in other countries. Therefore, some  
172 manufacturers may be reluctant to introduce their medical devices in countries with  
173 underdeveloped regulatory systems, which makes it difficult for the population to access much-  
174 needed medical devices. Conversely, the respective NRAs must provide balance by ensuring  
175 public health and users' protection through approved, safe, effective, acceptable quality and  
176 performance medical devices (10). The readiness of the MCAZ to effectively regulate medical  
177 devices beyond condoms and gloves is unknown. MCAZ is a statutory body established by  
178 Parliament, The Medicines and Allied Substances Control Act (MASCA) [Chapter 15.03], to  
179 regulate medicines and Allied Substances. Therefore, benchmarking the MCAZ is crucial in  
180 assessing its readiness to regulate medical devices effectively (17).

181

182 The study is significant because Zimbabwe is expanding the regulatory system by expanding  
183 the scope of health products regulated to include IVDs. Fundamentally, independent and  
184 objective benchmarking be conducted to identify strengths and deficiencies. The benchmarking  
185 needs to be standardised according to globally acceptable standards. The WHO GBT is one of  
186 the globally acceptable ways of benchmarking the maturity level of NRAs (18). The tool uses  
187 a set of indicators to evaluate the NRA. It uses it as input in developing a road map to guide  
188 establishing, implementing and maintaining an effective medical devices regulatory system.  
189 Additionally, the road map works as a tool for the regulatory system to be responsive,

190 predictable, transparent and proportional to the public health risks will ensure the population  
191 access to safe and acceptable quality and performance medical devices.

192

## 193 **Methods**

### 194 **Study design**

195 We conducted a quantitative study using the WHO GBT+ medical devices methodology to  
196 evaluate the medical devices regulatory oversight at the MCAZ in Zimbabwe between June  
197 and August 2022. The following regulatory functions were assessed following the medical  
198 devices' life cycle:

199

- 200 • National Regulatory System (RS)- The legal and regulatory framework supports the  
201 regulatory system's functions to ensure the quality, safety, and performance of medical  
202 products.
- 203 • Registration and Market Authorisation (MA)- The issuance of marketing authorisations  
204 (also referred to as product licensing or registration) when medical products have met  
205 the requirements of standardised conformity assessment.
- 206 • Vigilance (VL)- The science and activities relating to the prevention, detection,  
207 assessment, and understanding of adverse effects or any other medical product-related  
208 problems for guaranteeing that medical product continues to meet quality, safety and  
209 performance requirements throughout the product's lifecycle.
- 210 • Market Surveillance and Control (MC)-The function of assuring ongoing compliance  
211 of the products placed on the market with quality, safety and performance requirements.
- 212 • Licensing Establishment (LE) - The function of guaranteeing the quality, safety, and  
213 performance of medical products used within or exported out of the country through



214 licensing of establishments involved in the value chain and life cycle of the medical  
215 products.

216 • Regulatory Inspection (RI)-Auditing establishments throughout the value chain and life  
217 cycle of medical devices to ensure compliance of these establishments with laws,  
218 regulations, approved standards, norms, and guidelines.

219 • Laboratory Testing(LT)- The independent performance verification of the  
220 manufacturer's performance claims by the NRA to support premarket approval or a  
221 variation or change to marketing authorisation.

222 • Clinical Trials (CTs) Oversight- Refers to the legal mandate of the NRA to authorise,  
223 regulate and, if necessary, terminate CTs.

224

225 The regulatory functions were assessed using a set of indicators that were divided into the  
226 following nine categories:

227 1. Legal provisions, regulations and guidelines.

228 2. Organisation and governance.

229 3. Policy and strategic planning.

230 4. Leadership and crisis management.

231 5. Transparency, accountability and communication.

232 6. Quality and risk management systems.

233 7. Regulatory process.

234 8. Resources (including Human, financial, infrastructure, equipment and information  
235 management systems).

236 9. Monitoring progress and assessing impact.

237

238 Sub-indicators are grouped under a parent indicator to compile overall scores (19).

239

240

### 241 **Study setting**

242 The benchmarking of the MCAZ was conducted between June and August 2022 since the  
243 institution is a statutory body established to regulate medicines and allied substances according  
244 to the Medicines and Allied Substances Control Act (MASCA) [Chapter 15.03].

245

### 246 **Data Analysis**

247 Descriptive analysis was performed to describe the quality of regulatory function  
248 implementation based on the cumulative score of sub-indicators. The Computerised GBT  
249 (cGBT) scoring algorithm was used to determine the implementation status of each indicator  
250 for each regulatory function. Scoring was done as a measure of assessing the quality of the  
251 implementation of each sub-indicator as follows:

252

- 253 1. Not implemented (NI): no evidence was provided to demonstrate any degree of  
254 implementation of the sub-indicator. This status was assigned where a score of 0% as a  
255 percentage is attained.
- 256 2. Ongoing implementation (OI): some actions/steps/activities were taken towards  
257 implementing the concerned sub-indicator. However, the sub-indicator still needs to be  
258 implemented in full. A score of 25% was assigned to this category (a score of 25% as  
259 a percentage).
- 260 3. Partially implemented (PI): some actions/activities showed the full implementation of  
261 the sub-indicator; however, such full performance is recent or relatively new, with little  
262 cumulative data for consistent execution. Supporting documented evidence was  
263 expected to show the current full implementation of the concerned sub-indicator. For

264 mathematical scoring, 'partially implemented' is scored as 0.75 out of one (i.e., 75% as  
265 a percentage).

266 4. Fully implemented (I): some actions/activities demonstrate the consistent and full  
267 implementation of the sub-indicator over time. Supporting evidence is expected to  
268 illustrate the full, consistent implementation of the sub-indicator (i.e., shown over time  
269 and through repetition of the process and outcome). 'Fully implemented' is scored as  
270 one out of one (i.e., 100% as a percentage).

271

272 The cGBT algorithm was used to assign maturity levels (MLs) based on the cumulative scoring  
273 of the sub-indicators under that function. For a regulatory function to reach a specific ML, a  
274 specified percentage of sub-indicators must be scored as 'fully implemented' (19).

275

## 276 **Ethical Considerations**

277 Ethical approval for this study was obtained from the Medical Research Council of Zimbabwe  
278 (MRCZ/A/2900). Participation was voluntary. Participants were able to stop the interview at  
279 any time without explanation. Written informed consent was obtained from each study  
280 participant before each interview. The interview content and the interviewee's identity were  
281 kept anonymous.

282

## 283 **Results**

284 The regulatory functions that were assessed were all at maturity level 1. Maturity level 1 is the  
285 minor level to measure each indicator's implementation quality. Figure 1 shows the maturity  
286 level of each regulatory function. The Lot Release regulatory function was not assessed  
287 because it does not apply to medical devices.

288

289 The quality of implementation of each regulatory function ranged between 18% to 88%.  
290 Clinical Trial was the least, with 18%, and Laboratory Testing scored 88%. Figure 2 shows the  
291 performance of each regulatory function that was assessed.

292

293 The national regulatory system function did not have explicit legal provisions and regulations  
294 that required medical devices to meet specific safety, quality and performance requirements  
295 throughout their lifecycle. Additionally, the MASCA did not define the roles and  
296 responsibilities of institutions involved in the medical devices regulatory system. Similarly,  
297 there were no legal provisions and relevant regulations to take action on the recall, suspension,  
298 withdrawal and destruction of SF medical devices.

299

300 MA function fell short in legal provisions and regulations that mandate medical devices to be  
301 assessed against stipulated requirements before accessing the market. No requirements require  
302 medical devices to be subjected to a conformity assessment proportional to the medical device's  
303 risk class. Draft IVDs regulations were in place pending approval for implementation.

304

305 The VL function was not robust enough to prevent, detect, assess, and understand the adverse  
306 effects or any other medical device-related problems throughout the medical devices' lifecycle,  
307 except for condoms and gloves.

308

309 Efforts were ongoing to address market surveillance and controls. There were no legal  
310 provisions and regulations to control import activities. However, Import and Export regulations  
311 for medical devices were in draft format, pending approval. Legal provisions and regulations  
312 authorise market surveillance and control activities, including product sampling from different  
313 supply chain points, were unavailable. The NRA did not have legal provisions and regulations

314 to address its role in dealing with SF medical devices.

315

316 No legal provisions and regulations required economic operators involved throughout the value  
317 chain of medical devices to be registered based on Good Practices (GXP) compliance.  
318 Furthermore, there were no legal provisions to empower the NRA to issue, suspend or revoke  
319 licenses for establishments for medical devices besides condoms and gloves.

320

321 No legal provisions, regulations or guidelines were required to define the regulatory framework  
322 of inspection and enforcement for medical devices, except for condoms and gloves.  
323 Additionally, there were no updated national GXP regulations, norms or guidelines that are  
324 mandatory to guide economic operators on their submissions.

325

326 The laboratory testing function was well established and implemented for condoms and gloves.  
327 Although the legal basis is unclear, demonstrable steps have been taken towards establishing  
328 one for IVD medical devices. In addition, there is no evidence of legal provisions or regulations  
329 allowing reliance on and recognition of other laboratories' regulatory decisions.

330

331 There were no legal provisions or regulations for CT oversight. Moreover, no legal provisions  
332 or regulations required notification to and authorisation from the NRA diversions from the  
333 original protocol of the CTs. Lastly, there was no evidence of legal provisions, regulations or  
334 guidelines requiring that investigational medical products (IMPs) comply with good  
335 manufacturing practices for IMPs.

336

337 Cross-cutting indicators were generally in place; policy and strategic planning, leadership and  
338 crisis management, transparency, accountability and communication, quality and risk

339 management systems, regulatory process, resources (Human, financial, infrastructure,  
340 equipment and information management systems), monitoring progress and assessing impact.  
341 However, the indicators were sufficient for regulating condoms and gloves only. There were  
342 some vacant staff positions compared to the current establishment of the NRA. The competence  
343 framework was sufficient for the existing scope of regulated medical devices (condoms and  
344 gloves) but not for other medical devices. Transparency and accountability needed to be  
345 improved as the NRA was not publishing public reports, excerpts of regulatory assessments  
346 conducted (market authorisation, laboratory or inspection reports), and lists of all approved or  
347 rejected applications.

## 348 **Discussion**

349

350 RS

351 Medical devices, including IVDs in Zimbabwe, are not adequately regulated due to the low  
352 score of less than 80%. The ineffective regulation of these health products is because of an  
353 underdeveloped legislative framework. The MASCA was promulgated specifically to regulate  
354 medicines and Allied Substances. However, the term "Allied Substances" was not defined,  
355 leaving a gap in the scope of products that can be regulated under this legislation. Hubner et al.  
356 concluded that the Zimbabwean legislation did not define medical devices (9). Therefore, our  
357 finding is consistent with Hubner et al.'s finding.

358

359 The MCAZ seems not to have a clear mandate to regulate medical devices. The implications  
360 are the non-regulation of medical devices because of the undefined regulatory framework for  
361 the national regulatory system. Considering no standard definition of medical devices and the

362 lack of a well-defined regulatory framework may have resulted in the unavailability of essential  
363 principles of safety and performance and risk-based classification of medical devices, as  
364 concluded by Hubner et al. Overall, the maturity level of the regulatory system was found to  
365 be ML 1, which is consistent with the conclusion by Hubner et al. that Zimbabwe did not have  
366 a formal regulatory process for medical devices, except for some aspects to regulate condoms  
367 and gloves (9).

368

369 The findings clearly show that Zimbabwe's medical devices regulatory system has not been  
370 responsive, outcome-oriented, predictable, risk proportionate to public health risk and  
371 independent; these are critical characteristics of a robust regulatory system. The finding agrees  
372 with what Dube-Mwedzi et al. said about efforts to strengthen regulatory frameworks for  
373 medicines, whilst focus on medical devices has been lower (13). Yet, poor-quality medical  
374 devices significantly impact healthcare outcomes. It is widely accepted now that the value of  
375 medication rests mainly on the accuracy of the diagnosis. Thus, using poor-quality medical  
376 devices and diagnostics undermines the effectiveness of efforts to make good quality, safe and  
377 effective medicines available. Investing more efforts into strengthening frameworks for  
378 medical devices could be recommended as a priority for the SADC countries. Dube-Mwedzi  
379 also stressed the need to strengthen governance to make the national regulatory authority more  
380 efficient. Looking at the Zimbabwean context, following an institutional approach that involves  
381 implementing the "best practices" seems plausible to harmonise the regulations. The other  
382 option requires experimentation and prioritisation of country-specific challenges, which may  
383 be challenging and costly for countries without experience. The problem-driven approach  
384 diverges from the institutional approach by prioritising country-specific issues and  
385 enforcement over the blanket implementation of "best practices." This approach allows for  
386 feedback loops and greater policy experimentation as problems arise (20). Therefore, the

387 MCAZ must be empowered to regulate medical devices based on a solid legal foundation. The  
388 methodology in our study differed from Dube-Mwedzi et al.'s because the latter focused on the  
389 SADC member states, and the data presented needed to be more granular to identify where  
390 Zimbabwe stood in the study. In our study, we had an in-depth look at the Zimbabwean context.

391

392 Furthermore, the methodology in this study looked at registration and licensing (import and  
393 export controls), clinical testing and PMS regulatory functions. In addition to the stated  
394 regulatory functions, the study conducted by this researcher looked further at indicators specific  
395 to regulatory systems, market authorisation, Licensing establishment, product performance  
396 evaluation, and regulatory inspection and quality management system audits. The findings on  
397 the additional regulatory functions are stated below.

398

399

400

401 MA

402 The quality of performance for this regulatory function was 44% due to the lack of legal  
403 provisions and regulations to mandate the registration of medical devices before accessing the  
404 market. The legal provisions, regulations and guidelines for medical devices should also  
405 support notification/listing low-risk products. The International Medical Devices Regulatory  
406 Framework (IMDRF) and its predecessor, the Global Harmonisation Working Party (GHTF),  
407 recommend that medical devices be assigned to one of four classes based on a set of rules. This  
408 assignment determines the level of scrutiny the device is subjected to for conformity  
409 assessment. Class A devices offer the lowest risk, Class B low to moderate hazard, Class C



410 moderate to high risk, and Class D the highest risk. The level of regulatory oversight and the  
411 evidence required to support the product's conformity assessment to Essential Principles for  
412 Safety and Performance becomes more robust and demanding as the device's classification  
413 increases from A to D (21,22). Medical devices other than condoms and gloves are not quality  
414 assured and marketed without undergoing a process of evaluation to determine the product's  
415 quality, safety, and performance. There is no assurance that only medical devices the NRA has  
416 duly authorised are allowed to be manufactured, imported, distributed, sold or supplied to end  
417 users.

418 VL

419 The vigilance regulatory function had a quality score of 27% due to the lack of legal provisions,  
420 regulations, and guidelines required to define the regulatory framework of vigilance, leaving  
421 the Zimbabwean population at risk of medical devices that do not continue to meet  
422 requirements for quality, safety and performance throughout the product's lifecycle. An  
423 established, implemented and maintained reporting system must be established to monitor  
424 medical device quality, safety and performance. The regulatory function is essential because  
425 even mature regulatory jurisdictions such as USFDA and the EU were not spared from adverse  
426 incidents and recalls of medical devices, which called for an overhaul of the regulatory system  
427 in the EU context (8). These deficiencies imply that the magnitude of adverse events related to  
428 medical devices is unknown in the Zimbabwean context. The human and economic costs of  
429 these deficiencies can be severe. Legislation must mandate the economic operators  
430 (manufacturers, importers, distributors, authorised representatives and wholesalers) to collect  
431 and evaluate the experiences gained from medical devices placed on the market. The economic  
432 operators must record and investigate any incident report they receive, implement field safety  
433 corrective action proportional to the identified deficiency and inform the regulatory authority  
434 when the law demands so. Regulators must be informed when there is a severe public health

435 threat or when death or serious deterioration in health occurred or may have occurred to the  
436 user, patient or another person. The incident may be linked to the medical device's quality,  
437 safety or performance. The regulatory authority may monitor the manufacturer's investigation  
438 to determine the root cause (4,5).

439 MC

440 An effort has been made to establish import and export regulations for medical devices  
441 attaining a 40% score. However, there are no legal provisions concerning import activities,  
442 including permanent regulatory intervention at designated entry and exit ports where medical  
443 devices are moved. Similarly, there were no legal provisions to authorise market surveillance  
444 and control activities, including medical device sampling from different supply chain points.  
445 These deficiencies expose the country to SF medical devices and may compromise:

- 446 • patients' safety and health outcomes,
- 447 • national economy due to the disease burden,
- 448 • public trust in the healthcare system, and
- 449 • the international fight against serious health challenges such as malaria and  
450 antimicrobial resistance (23).

451 Additionally, the lack of legal provisions and regulations addressing the role of NRA in dealing  
452 with SF medical products makes it challenging to implement this regulatory function at the  
453 present moment.

454 There is a shortage in the literature regarding SF medical products in Africa and the Middle  
455 East. Studies have been mainly on medicines; this clearly shows that more needs to be done  
456 regarding SF medical devices and must be prioritised to ensure acceptable quality, safety and  
457 performance of medical devices (23). Challenges in managing medical products have been  
458 documented in the SADC region; however, more needs to be known regarding medical devices,

459 including IVDs. A study conducted to map existing frameworks, mechanisms and approaches  
460 to prevention, detection and response (PDR) to SF medical products concluded that most  
461 countries had the legal mandate to implement measures to curb SF medical products. Still, they  
462 were not doing so (14). Product failures have been reported in the United States (US) and  
463 European Union, resulting in regulatory regime reforms. The US and EU regulations are highly  
464 esteemed. However, high incidences of clinical adverse events, high recall rates, and frequent  
465 phase-out of some medical devices have resulted in overhauling the regulations (8). The  
466 problem may be more for a country like Zimbabwe that needs legislation to curb SF medical  
467 devices.

468 LI

469 There were no legal provisions, regulations, or guidelines for licensing economic operators  
470 along the value chain of medical devices resulting in an overall score of 62%. The score implies  
471 that economic operators involved in the medical devices supply chain are not licensed using a  
472 licensing regime that is proportional to the role in the medical device's value chain and the  
473 medical device's risk classification. Consequently, there is no traceability of medical devices  
474 throughout the supply chain of medical devices, except for condoms and gloves. The NRA  
475 must be empowered by legislation to issue licenses and suspend or revoke establishment  
476 permits. In cases of post-licensing changes, the legislation or regulations must require the  
477 economic operators to notify the regulatory authority.

478 LT

479 The laboratory testing regulatory function had the highest score (88%) due to the lab testing  
480 conducted for condoms and gloves, excluding other medical devices, including IVDs. This  
481 score may be due to assessments by external bodies since the laboratory is ISO 17025  
482 accredited. However, due to the wide range and complexities of medical devices, medical

483 devices other than condoms and gloves are not independently verified by laboratory testing  
484 where applicable based on the risk class of the medical device. The non-verification for market  
485 authorisation, vigilance, market surveillance and control or post-authorisation changes exposes  
486 the population to the risk of SF medical devices. Due to the wide range of medical devices and  
487 the associated laboratory expertise, the NRA may outsource part or most laboratory testing.  
488 The details of the outsourced testing services' responsibilities, duties and roles in these  
489 structures should be clearly defined and documented, including their accreditation status. The  
490 NRA must implement mechanisms to select, monitor and evaluate laboratories performing  
491 laboratory work before fulfilling the regulatory requirements. The evaluation may be done  
492 through onsite audits using ISO 15189 and ISO 17025 requirements to assess policies and  
493 procedures for the tests conducted in individual laboratories. Having an ISO accreditation is a  
494 good starting point. However, more is needed, as anecdotal evidence has shown that labs that  
495 may have ISO 15189 accreditation failed the audit conducted by the WHO for the labs to be  
496 listed as WHO Performance Evaluation Laboratories (PEL) for IVDs.

497 Performance evaluation is critical to verify a manufacturer's claims for a medical device.  
498 Therefore, it is of paramount importance for the NRA to conduct an assessment and analysis  
499 of data to establish or verify the scientific validity, the analytical and, where applicable, the  
500 clinical performance of a medical device to ensure that the intended purpose and the  
501 classification is appropriate based on the specific disorder, condition or risk factor of interest  
502 that it is intended to detect, define or differentiate(4,5).

### 503 RI

504 The regulatory inspection had an implementation quality score of 68% due to market  
505 authorisation inspections conducted for establishments involved in the supply chain of  
506 condoms and gloves. However, legal provisions, regulations and guidelines for regulatory

507 inspection were not explicit for medical devices. Establishments involved in other medical  
508 devices besides condoms and gloves are unknown regarding compliance with perceived  
509 standards. The NRA must publish the list of measures that all the economic operators must  
510 comply with, and these standards must be the basis upon which the economic operators are  
511 audited for compliance. Regulatory inspection activities must be supported by a comprehensive  
512 set of legal provisions, regulations and guidelines which provide the necessary mandate to  
513 implement all activities related to this regulatory function.

514 *CT Oversight.*

515 The CT oversight regulatory scored the least (18%). The MASCA mentions clinical trials in  
516 the context of medicines only, but not for medical devices. Some classes of medical devices  
517 require clinical trials to be conducted to support registration and market authorisation of these  
518 products. Before registration and market authorisation, the products are classified as IMPs. The  
519 NRA needs to oversee these products before, during and after the implementation of CTs. The  
520 NRA must have the legal mandate to authorise, regulate and, if necessary, terminate CTs in  
521 line with the international medical research ethics guidelines and principles. Before the trial  
522 commences, the NRA should have trained and competent staff to review CT protocols, also  
523 reviewed by an Independent Ethics Committee (IEC). The IEC should review the protocols  
524 and should have the authority, when necessary, to require protocol revisions. The CT review  
525 committee should comprise members that are competent and skilled and ensure that there is no  
526 conflict of interest. The finding in this study is that there is CT oversight by the NRA for  
527 investigational medical devices undergoing CT in Zimbabwe due to the lack of the following:

- 528
- Legal provisions and regulations for CTs oversight.

- 529       • Legal provisions and regulations require research centres, researchers, sponsors,  
530           clinical research organisations (CROs) and all relevant institutions in the clinical trial  
531           to comply with good clinical practice (GCP).
- 532       • Legal provisions and regulations stipulate that authorisation from NRA and notification  
533           to the NRA are required where there are changes to the original protocol or any relevant  
534           documents of the CT.
- 535       • Legal provisions, regulations and guidelines require that IMPs comply with good  
536           manufacturing practice (GMP) for IMPs.
- 537       • Legal provisions or regulations cover circumstances where the routine CT evaluation  
538           and procedure may not be followed (e.g. for public-health interests).
- 539       • Legal provisions, regulations or guidelines exist for NRA to inspect, suspend or stop  
540           CTs.

541   These deficiencies subject the Zimbabwean population to products needing acceptable quality,  
542   safety and performance during CTs.

543   Furthermore, the NRA is unaware of the CTs conducted and those in progress; the research  
544   participants' rights are not guaranteed because the participants are uninformed. This is  
545   unacceptable today, considering the previous well-documented violations: "*Tuskegee Syphilis*  
546   *Study from 1932 to 1972, Nazi medical experimentation in the 1930s and 1940s, and research*  
547   *conducted at the Willowbrook State School in the 1950s and 1960s. As the aftermath of these*  
548   *practices, wherein uninformed and unaware patients were exposed to a disease or subject to*  
549   *other unproven treatments, became known, the need for rules governing the design and*  
550   *implementation of human-subject research protocols became very evident."* (24).

551   Cross-cutting indicators were generally in place; policy and strategic planning, leadership and  
552   crisis management, transparency, accountability and communication, quality and risk

553 management systems, regulatory process, resources (Human, financial, infrastructure,  
554 equipment and information management systems), monitoring progress and assessing impact.  
555 However, the indicators were sufficient for regulating condoms and gloves only. There were  
556 some vacant staff positions compared to the current establishment of the NRA. The competence  
557 framework was sufficient for the existing scope of products. There is a need to review the  
558 operational and competency framework to meet the scope and complexity of other medical  
559 devices. The competency framework must include the following aspects:

- 560 • Scientific and Health Concepts: Understanding and applying “evolving basic and  
561 translational science, regulatory science and public health concepts to drive new  
562 approaches to improve healthcare product development, review and oversight” (25)
- 563 • Ethics: Ability to integrate and demonstrate core values, integrity and accountability.
- 564 • Business Acumen: Ability to successfully leverage systems and processes to operate a  
565 regulatory function.
- 566 • Communication: Ability to convey or exchange information with stakeholders within  
567 and outside the organisation.
- 568 • “Leadership: Ability to direct and contribute to initiatives within the organisation, with  
569 groups engaged in developing good regulatory practice and policy, and within the  
570 regulatory profession.
- 571 • Regulatory Frameworks and Strategy: Knowledge of regulatory frameworks and  
572 external environments and the ability to apply these to regulatory solutions throughout  
573 the product lifecycle.
- 574 • Product Development and Registration: Knowledge of the research and development,  
575 preclinical and clinical steps and related regulations in healthcare product development.
- 576 • Postapproval/Post-market: Knowledge of requirements and processes for maintaining  
577 a product on the market, reporting and surveillance”(25,26)

578 The NRA needs to improve mechanisms to promote transparency, accountability and  
579 communication by publishing summary technical evaluation reports for approved  
580 registration MA, inspections, and rejected applications.

### 581 **Study Limitations**

582 The study was conducted in the context of MCAZ as the NRA. However, the Medical  
583 Laboratory and Clinical Scientists Council of Zimbabwe and the National Microbiology  
584 Reference Laboratory were not benchmarked. The two institutions register IVD Medical for  
585 priority pathogens. The registration is used as an eligibility criterion for products to be  
586 procured through the national tendering process.

### 587 **Conclusions**

588 The readiness of the NRA in Zimbabwe to regulate medical devices is below optimum as it is  
589 at the lowest possible score that can be attained using the GBT+ medical devices methodology.  
590 The NRA does not have an explicit legal mandate to regulate medical devices. The MASCA  
591 needs more clarity on legal provisions for medical devices regulatory system framework,  
592 registration and market authorisation, vigilance, market surveillance control, licensing  
593 establishment, regulatory inspection, laboratory testing and clinical trials. The legal provisions,  
594 regulations, and guidelines are inadequate for effectively regulating medical devices. The  
595 medical devices regulation requires review for it to be robust and fit-for-purpose, responsive,  
596 oriented to the outcome, predictable based on a standard and transparent approach, and the  
597 level of scrutiny proportionate to the risk classification of the medical device.

598

### 599 **Acknowledgements**



600 The authors would like to acknowledge the cooperation of the staff at NRA IN Zimbabwe for  
601 their assistance during the interviews and availing the evidence for the assessment to be  
602 successful.


603

## 604 **References**

- 605 1. Sabet Sarvestani A, Sienko KH. Medical device landscape for communicable and  
606 noncommunicable diseases in low-income countries [Internet]. Vol. 14, Globalization  
607 and Health. Global Health; 2018 [cited 2022 Jul 30]. Available from:  
608 <https://pubmed.ncbi.nlm.nih.gov/29973232/>
- 609 2. World Health Organization. WHO global model regulatory framework for medical  
610 devices including in vitro diagnostic medical devices. [Internet]. WHO Medical device  
611 technical series. Licence: CC BY-NC-SA 3.0 IGO. 2017. 68 p. Available from:  
612 [https://www.who.int/medical\\_devices/publications/global\\_model\\_regulatory\\_framework\\_meddev/en/](https://www.who.int/medical_devices/publications/global_model_regulatory_framework_meddev/en/)  
613
- 614 3. GHTF. Global Harmonization Task Force Study Group 1: Definition of the Terms  
615 ‘Medical Device’ and ‘In Vitro Diagnostic (IVD) Medical Device.’ Force, Study Gr 1  
616 Glob Harmon Task [Internet]. 2012;(Ivd):6. Available from:  
617 [http://www.imdrf.org/docs/ghtf/final/sg1/technical-docs/ghtf-sg1-n071-2012-  
618 definition-of-terms-120516.pdf#search=%22ghtf definition ?Medical Device?  
619 2012%22](http://www.imdrf.org/docs/ghtf/final/sg1/technical-docs/ghtf-sg1-n071-2012-definition-of-terms-120516.pdf#search=%22ghtf%20definition%20Medical%20Device%202012%22)
- 620 4. European Commission. Regulation (EU) 2017/745 of The European Parliament and of  
621 the Council on Medical Devices. Off J Eur Union. 2017;5(8):175.
- 622 5. European Commission. Regulation (EU) 2017/746 of the European parliament and of  
623 the council on in vitro diagnostic medical devices. Off J Eur Union. 2017;5(5):117–76.
- 624 6. REGULATORY AFFAIRS PROFESSIONALS SOCIETY.  
625 *Fundamentals\_of\_Medical\_Device\_Regulations\_\_Fifth\_.pdf*. Fifth. Hall GN, editor.  
626 Rockville: RAPS BOOKS; 2022. 748 p.
- 627 7. Jarow JP, Baxley JH. Medical devices: US medical device regulation [Internet]. Vol.  
628 33, Urologic Oncology: Seminars and Original Investigations. Urol Oncol; 2015 [cited  
629 2022 Jul 30]. p. 128–32. Available from: <https://pubmed.ncbi.nlm.nih.gov/25458071/>
- 630 8. Campillo-Artero C. A full-fledged overhaul is needed for a risk and value-based  
631 regulation of medical devices in Europe. Health Policy (New York). 2013 Nov  
632 1;113(1–2):38–44.
- 633 9. Hubner S, Maloney C, Phillips SD, Doshi P, Mugaga J, Ssekitoileko RT, et al. The  
634 evolving landscape of medical device regulation in East, Central, and Southern Africa.  
635 *Glob Heal Sci Pract* [Internet]. 2021 Apr 1 [cited 2021 Nov 10];9(1):136–48.  
636 Available from: <https://pubmed.ncbi.nlm.nih.gov/33764886/>
- 637 10. De Maria C, Di Pietro L, Díaz Lantada A, Madete J, Makobore PN, Mridha M, et al.  
638 Safe innovation: On medical device legislation in Europe and Africa. *Heal Policy*  
639 *Technol* [Internet]. 2018;7(2):156–65. Available from:  
640 <https://doi.org/10.1016/j.hlpt.2018.01.012>


- 641 11. Addae-Mensah I, Beltramini H, Haggag AA, Hoogmartens J, Shaohong J, Molzon JA,  
642 et al. WHO Expert Committee on specifications for pharmaceutical preparations.  
643 World Health Organization - Technical Report Series. 2006.
- 644 12. World Health Organization. Health products policy and standards : Good  
645 Manufacturing Practices [Internet]. 2018 [cited 2023 May 21]. Available from:  
646 [https://www.who.int/teams/health-product-policy-and-standards/assistive-and-medical-](https://www.who.int/teams/health-product-policy-and-standards/assistive-and-medical-technology/medical-devices/regulations)  
647 [technology/medical-devices/regulations](https://www.who.int/teams/health-product-policy-and-standards/assistive-and-medical-technology/medical-devices/regulations)
- 648 13. Dube-Mwedzi S, Kniazkov S, Nikiema JB, Kasilo OMJ, Fortin A, Tumusiime P, et al.  
649 A rapid assessment of the National Regulatory Systems for medical products in the  
650 Southern African Development Community [Internet]. Vol. 13, Journal of  
651 Pharmaceutical Policy and Practice. J Pharm Policy Pract; 2020 [cited 2021 Nov 10].  
652 Available from: <https://pubmed.ncbi.nlm.nih.gov/33029353/>
- 653 14. Kniazkov S, Dube-Mwedzi S, Nikiema JB. Prevention, Detection and Response to  
654 incidences of substandard and falsified medical products in the Member States of the  
655 Southern African Development Community [Internet]. Vol. 13, Journal of  
656 Pharmaceutical Policy and Practice. J Pharm Policy Pract; 2020 [cited 2022 Jul 29].  
657 Available from: <https://pubmed.ncbi.nlm.nih.gov/33088577/>
- 658 15. Kniazkov S, Dube-Mwedzi S, Nikiema JB. Prevention, Detection and Response to  
659 incidences of substandard and falsified medical products in the Member States of the  
660 Southern African Development Community [Internet]. Vol. 13, Journal of  
661 Pharmaceutical Policy and Practice. John Wiley & Sons, Ltd; 2020 [cited 2021 Sep  
662 19]. p. e25229. Available from:  
663 <https://onlinelibrary.wiley.com/doi/full/10.1002/jia2.25229>
- 664 16. Guzman J, O’Connell E, Kikule K, Hafner T. The WHO Global Benchmarking Tool:  
665 A game changer for strengthening national regulatory capacity [Internet]. Vol. 5, BMJ  
666 Global Health. 2020. p. 3181. Available from: <http://gh.bmj.com/>
- 667 17. MCAZ. Chapter 15 : 03 MEDICINES AND ALLIED SUBSTANCES CONTROL  
668 ACT [Internet]. 2014. Available from:  
669 <https://www.mcaz.co.zw/index.php/downloads/category/7-regulations>
- 670 18. Khadem Broojerdi A, Baran Sillo H, Ostad Ali Dehaghi R, Ward M, Refaat M, Parry  
671 J. The World Health Organization Global Benchmarking Tool an Instrument to  
672 Strengthen Medical Products Regulation and Promote Universal Health Coverage.  
673 Front Med. 2020 Aug 19;7:457.
- 674 19. World Health Organization. Manual for benchmarking of the national regulatory  
675 system of medical products and formulation of institutional development plans.  
676 2021;(February):1–81. Available from: [https://cdn.who.int/media/docs/default-](https://cdn.who.int/media/docs/default-source/medicines/regulation-systems/benchmarking_manual_v2_09mar2021_clean.pdf?sfvrsn=33b0038d_5&download=true)  
677 [source/medicines/regulation-](https://cdn.who.int/media/docs/default-source/medicines/regulation-systems/benchmarking_manual_v2_09mar2021_clean.pdf?sfvrsn=33b0038d_5&download=true)  
678 [systems/benchmarking\\_manual\\_v2\\_09mar2021\\_clean.pdf?sfvrsn=33b0038d\\_5&down](https://cdn.who.int/media/docs/default-source/medicines/regulation-systems/benchmarking_manual_v2_09mar2021_clean.pdf?sfvrsn=33b0038d_5&download=true)  
679 [load=true](https://cdn.who.int/media/docs/default-source/medicines/regulation-systems/benchmarking_manual_v2_09mar2021_clean.pdf?sfvrsn=33b0038d_5&download=true)
- 680 20. Andrews M, Pritchett L, Woolcock M. Escaping Capability Traps Through Problem  
681 Driven Iterative Adaptation (PDIA). World Dev. 2013;51(June 2012):234–44.
- 682 21. Global Harmonization Task Force. Principles of Medical Devices Classification.  
683 2006;1–27. Available from:  
684 <https://www.imdrf.org/sites/default/files/docs/ghtf/final/sg1/technical-docs/ghtf-sg1->

- 685 n15-2006-guidance-classification-060627.pdf
- 686 22. (MDCG) MDCG. Guidance on classification of medical devices. Mdcg 2021-24  
687 [Internet]. 2021 [cited 2022 Jul 29];1–11. Available from:  
688 [https://health.ec.europa.eu/latest-updates/updated-joint-implementation-plan-actions-](https://health.ec.europa.eu/latest-updates/updated-joint-implementation-plan-actions-considered-necessary-ensure-sound-functioning-new-2022-02-07_en)  
689 [considered-necessary-ensure-sound-functioning-new-2022-02-07\\_en](https://health.ec.europa.eu/latest-updates/updated-joint-implementation-plan-actions-considered-necessary-ensure-sound-functioning-new-2022-02-07_en)
- 690 23. Sweileh WM. Substandard and falsified medical products: bibliometric analysis and  
691 mapping of scientific research. *Global Health* [Internet]. 2021 Dec 1 [cited 2022 Jul  
692 29];17(1). Available from: <https://pubmed.ncbi.nlm.nih.gov/34556126/>
- 693 24. Barrow JM, Brannan GD, Khandhar PB. Research Ethics. *StatPearls* [Internet]. 2022  
694 [cited 2023 Feb 4]; Available from: <https://pubmed.ncbi.nlm.nih.gov/29083578/>
- 695 25. Bridges W. The Creation of a Competent Global Regulatory Workforce. *Front*  
696 *Pharmacol.* 2019;10(March):1–6.
- 697 26. RAPS. Regulatory Competency Framework. 2021 [cited 2022 Jul 28]; Available from:  
698 <https://www.raps.org/resources/regulatory-competency-framework>
- 699
- 700



RS= Regulatory System, MA: Market Authorisation, VL: Vigilance, MC: Market Surveillance and Control,  
 LI: Licensing Establishment, RI: Regulatory Inspection, LT: Laboratory Testing, CT: Clinical Trials

**Figure 1. The Maturity Level for the Regulatory Functions assessed at MCAZ between June and August 2022.**



**Figure 2: Quality of Implementation of regulatory functions at MCAZ between June and August 2022.**